Plasma Transfusions in Haemophilia

Bradlow, Basil A.
March 1965
British Medical Journal;3/27/1965, Vol. 1 Issue 5438, p859
Academic Journal
No abstract available.


Related Articles

  • blood products. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p112 

    An encyclopedia entry for "blood products" is presented. The term refers to donated blood that is separated into red cells, white cells, platelets and plasma. An overview of the uses of each blood product in blood transfusion is offered. Concentrates of blood clotting factors VIII and IX are...

  • Before transfusion became established procedure. Boulton, Frank // BMJ: British Medical Journal (International Edition);11/06/99, Vol. 319 Issue 7219, p1257 

    Provides information on the role of Thomas Addis who transfused human phosphated blood to a patient with haemophilia in May 1910. Methods he used; Significance of his work; Other works of transfusing blood to a patient with haemophilia.

  • Recombinant Technology in Transfusion Medicine. Avent, Neil D. // Current Pharmaceutical Biotechnology;Sep2000, Vol. 1 Issue 2, p117 

    Recombinant technology in transfusion medicine has really only just begun to have large-scale impact. The preparation of blood products, determination of blood group phenotype, detection of blood group specific antibodies does not currently employ DNA-based methods for their preparation or...

  • Perspective: The fix is in. Pemberton, Stephen // Nature;11/27/2014 Supplement, Vol. 515 Issue s7528, pS165 

    The author discusses reasons why haemophilia researchers are wary of a possible cure for the disease. Haemophilia treatment-related tragedies such as the death of clinical trial patient Jesse Gelsinger in 1999 and transfusion of HIV-infected blood among hemophilia patients in the 1980s are...

  • Factor IX/nonacog-α.  // Reactions Weekly;7/9/2011, Issue 1359, p18 

    The article describes cases of allergic reactions during treatment with nonacog-α or plasma-derived factor IX for haemophilia B.

  • REKOMBINOWANY AKTYWNY CZYNNIK VII (rVIIa) -- WŁAÅšCIWOÅšCI FARMAKOLOGICZNE I ZASTOSOWANIE KLINICZNE. Zubkowicz, Marta; Chojnowski, Krzysztof // Problemy Terapii Monitorowanej;dec2007, Vol. 18 Issue 4, p245 

    Recombinant activated factor VII (rFVIIa; NovoSeven, NovoNordisk, Dennmark) was originally developed for the treatment of patients with haemophilia A and haemophilia B with inhibitory antibodies against factor VIII or factor IX. It has been approved in Europe for the treatment of haemorrhage in...

  • The development of psychological support for the Wales Inherited Bleeding Disorder service. Kelly, Lynne // Clinical Psychology Forum;May2015, Issue 269, p3 

    The article offers the author's insights regarding the development of psychological support for patients with haemophilia, a group of inherited bleeding disorders, in Wales. Topics discussed include several treatments, such as whole blood transfusions and cryoprecipitation, gaps in haemophilia...

  • Factor VIII/octocog-α: Factor VIII inhibitor development: case report.  // Reactions Weekly;Nov2013, Issue 1477, p17 

    The article presents a case study of a man with congenital haemophilia A who was treated with plasma-derived factor VIII or octocog-α (recombinant factor VIII) and developed factor VIII inhibitor.

  • Nonacog-α.  // Reactions Weekly;Feb2015, Vol. 1540 Issue 1, p221 

    The article presents a case study of a patient who had haemophilia B after switching from plasma-derives factor-IX treatment to nonacog-α treatment for dysgeusia.

  • Factor-VIII.  // Reactions Weekly;Sep2015, Vol. 1568 Issue 1, p130 

    The article presents a case study of a 46-year-old male patient who developed allergic reaction while consuming factor-VIII, plasma-derived factor VIII, for the treatment of his haemophilia A.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics